🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pranav Gandhi

AbbVie (United States)

ORCID: 0009-0008-8317-7712

Also affiliated with AbbVie (Japan)

MedicinePharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial”.

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Neurology(2022)10.1212/wnl.0000000000201568

N/A

1.4DataRank · unranked

30 citations

Patricia Pozo‐Rosich, Andrew Blumenfeld, Ye Li, Lawrence Severt, Jonathan Stokes +4 more

Early Improvements With Atogepant for the Preventive Treatment of Migraine

Neurology(2024)10.1212/wnl.0000000000210212

N/A

0.514DataRank · unranked

8 citations

Pranav Gandhi, Cristina Tassorelli, Uwe Reuter, Andrea M. Harriott, Dagny Holle +9 more

An item-level response shift study on the change of health state with the rating of asthma-specific quality of life: a report from the PROMIS® Pediatric Asthma Study

UNC Libraries(2020)10.17615/xw8r-sh69

N/A

0DataRank · unranked

0 citations

I‐Chan Huang, Pranav Gandhi, Bryce B. Reeve, Darren A. DeWalt, Carolyn E. Schwartz +1 more